<DOC>
	<DOCNO>NCT02342717</DOCNO>
	<brief_summary>To investigate whether extent co-administration multiple dose itraconazole affect single dose pharmacokinetics BI 425809 healthy male subject</brief_summary>
	<brief_title>Relative Bioavailability Single Oral Dose BI 425809 When Administered Alone Combination With Multiple Oral Doses Itraconazole Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<criteria>Inclusion criterion : Healthy male subject accord investigator 's assessment , base complete medical history include physical examination , vital sign ( BP , PR ) , 12lead ECG , clinical laboratory test Age 18 50 year ( incl . ) Body mass index ( BMI ) 18.5 29.9 kg/m2 ( incl . ) Signed date write informed consent prior admission study accordance GCP local legislation Exclusion criterion : Any find medical examination ( include BP , PR ECG ) deviate normal judge clinically relevant investigator Repeated measurement systolic blood pressure outside range 90 140 mmHg , diastolic blood pressure outside range 50 90 mmHg , pulse rate outside range 50 90 bpm Any laboratory value outside reference range investigator considers clinical relevance Any evidence concomitant disease judge clinically relevant investigator Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Cholecystectomy and/or surgery gastrointestinal tract could interfere pharmacokinetics trial medication ( except appendectomy simple hernia repair ) Diseases central nervous system ( include limit kind seizure stroke ) , relevant neurological psychiatric disorder History relevant orthostatic hypotension , faint spell , blackout Chronic relevant acute infection History relevant allergy hypersensitivity ( include allergy trial medication excipients ) Intake drug long halflife ( 24 h ) within 30 day less 10 halflives respective drug prior administration trial medication Within 10 day prior administration trial medication , use drug might reasonably influence result trial might prolong QT/QTc interval Participation another trial investigational drug administer within 60 day prior plan administration trial medication Smoker ( 10 cigarette 3 cigar 3 pipe per day ) Inability refrain smoke specify trial day Alcohol abuse ( consumption 30 g per day ) Drug abuse positive drug screen Blood donation 100 mL within 30 day prior administration trial medication intend donation trial Intention perform excessive physical activity within one week prior administration trial medication trial Inability comply dietary regimen trial site A marked baseline prolongation QT/QTc interval ( QTc interval repeatedly great 450 m ) relevant ECG find screen A history additional risk factor Torsades de Pointes ( heart failure , hypokalemia , family history Long QT Syndrome ) Subject assess unsuitable inclusion investigator , instance , consider able understand comply study requirement , condition would allow safe participation study Male subject agree minimize risk female partner become pregnant first dose day two month trial completion . Acceptable method contraception comprise barrier contraception medically accept contraceptive method female partner ( intrauterine device spermicide , hormonal contraceptive least two month prior trial participation ) Known fructose intolerance , glucosegalactose malabsorption , saccharoseisomaltase deficiency History relevant liver disease disturbance liver function , jaundice , drug induce liver injury , DubinJohnson syndrome , Rotor syndrome , liver tumour Liver enzymes ( ALT , AST , GGT ) upper limit normal screening examination</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>